Navigation Links
Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
Date:6/19/2013

ain is important in abuse.  When we look at the critical period following dosing when the commonly abused drug oxycodone reaches maximum liking, NKTR-181 was not distinguished from placebo with respect to both drug-liking and feeling high.  These are two of the most important metrics that help us understand the abuse potential of a medicine.  Importantly, NKTR-181 was dosed as an oral liquid, which underscores that its less rewarding properties are inherent to this NCE and independent of any abuse-deterrent formulation.  These data, along with previous efficacy data, suggest NKTR-181 may be a major advance towards safer opioid therapy for the treatment of moderate to severe chronic pain."

The HAL study compared drug liking between each treatment group (oxycodone 40 mg, Placebo, and NKTR-181 100 mg, 200 mg, and 400 mg).  On the bipolar VAS scale (0-100), a score of 50 indicates that the subject "neither likes nor dislikes" the drug.  In the study, 40 mg of oxycodone oral solution resulted in a maximum mean drug liking score of 85, indicating a "strong liking" for the effects of oxycodone.  The oxycodone liking score was significantly different from placebo as early as 15 minutes after dosing and peaked at 60 minutes. In the placebo arm, the maximum mean drug liking score was 50, indicating that the subjects neither liked nor disliked the effects.  NKTR-181 dosing was similar to placebo with maximum mean drug liking VAS scores of 58, 58 and 63 for 100 mg, 200 mg and 400 mg, respectively.

"The data from this study are remarkable and clearly demonstrate that drug abusers could not discriminate NKTR-181 from placebo at doses that we know produced analgesia in the validated pain models from our Phase 1 studies," said Robert Medve MD, SVP and Chief Medical Officer of Nektar Therapeutics. "These data suggest that NKTR-181 could change the way we think about opioids and how we treat patie
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
2. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
3. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City
4. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
5. Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
6. Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
7. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
8. Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
9. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... YARDLEY, Pa. , Oct. 22, 2014 /PRNewswire/ ... of their animal health medications, a Global Pharmaceutical ... and Antares serialization technology and turnkey solution to ... Photo - http://photos.prnewswire.com/prnh/20141021/153438 ... The product that was serialized and aggregated by ...
(Date:10/22/2014)... ST. LOUIS , Oct. 21, 2014 /PRNewswire-USNewswire/ ... are often subtle or unnoticed, but new technology, ... patient outcomes and leading to earlier detection of ... now affects 29 million Americans. If left untreated, ... or even blindness. Recently, optometric ...
(Date:10/22/2014)... , Oct. 22, 2014   Surefire Medical ... infusion systems designed to maximize targeted delivery of embolization ... to announce that oncologist John R. Daniels , ... Cancer Center, and surgical oncologist Steven C. Katz ... joined the Company,s Scientific Advisory Board (SAB).    ...
Breaking Medicine Technology:Xyntek and Antares Serialization Solution Protects Pets Too! 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
... Science, public health, and regulatory highlights for this ... in this document is designed for credentialed journalists. Release ... June 6, 2011. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... not contain any regulatory or enforcement actions due to ...
... – Regulus Therapeutics Inc ., a biopharmaceutical company ... microRNAs, today announced publication in the ... in mice on the antagonism of microRNA-33 (miR-33). The ... demonstrated that antagonism of miR-33 with ...
Cached Medicine Technology:FDA News & Notes - Week of June 6, 2011 2Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33 2Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33 3Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33 4Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33 5Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33 6
(Date:10/22/2014)... 2014 On October 22, CBS will ... skin diseases both fictional and real. The Charles ... organization committed to advocacy and philanthropy in the battle ... the opportunity to impart truth and clarity about this ... are many misconceptions about Morgellons Disease (MD) ...
(Date:10/22/2014)... By Amy Norton ... -- Headlines remain riveted on the three Ebola cases in ... much bigger health threat to Americans. President Barack Obama ... response to the virus, which has infected two Dallas nurses ... this month at Texas Health Presbyterian Hospital. But the ...
(Date:10/22/2014)... Angeles, California (PRWEB) October 22, 2014 Hay ... 2.0: Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) ... field of Yoga & Recovery. This book is meant ... thrive in a life of recovery. , Recovery 2.0 ... the 12 Steps; Recovery 2.0 is a guide for what ...
(Date:10/22/2014)... October 22, 2014 Healthcare professionals ... their continuing education at home or on-the-go via ... to 20 brand new, premium Seminar-on-Demand CE courses. ... of over 2,000 hours of CE ... their educational experience. With such a diverse library, ...
(Date:10/22/2014)... PA (PRWEB) October 22, 2014 Richard ... as an industry leader with over 25 years experience. ... team leader in the areas related to EDI, B2B ... Carlson is an Editorial Advisory Board member for Pharmaceutical ... Educator. Blue Fin Group is a management and ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2
... The following is a,statement of SEIU spokesperson Andrew McDonald:, ... health and,vitality of any democratic organization., "For the last ... and full debate over the future of our union. For ... been the subject of,an even more vigorous debate -- in ...
... China, April 8, 2008 /Xinhua-PRNewswire-FirstCall/ --,Linkwell Corporation (Linkwell ... developer, manufacturer and distributor of healthcare related,disinfectants in ... year-end,financial results in a conference call on Wednesday, ... Company will release its 2007 year-end financial results ...
... rising on,everything from bread to education, and health care is ... a Medicaid patient in the home, the,urgent need for an ... to nurses and other home care advocates,visiting legislators today as ... cost of a nurse,s visit to a home care patient ...
... Mark your calendars for these,training and networking ... Detroit Chapter (IABC/Detroit)!, April 16 Luncheon Session: ... organization,s message impact its market,share? Find out when ... messaging has impacted today,s marketing landscape., Join ...
... School of Medicine and colleagues at Merck Serono Research ... receptor sites on some tumors in different places at ... combination therapy for certain types of cancer. , An ... called epidermal growth factor receptors (EGFR) sitting on their ...
... Newborns Vulnerable for Rare,Metabolic Conditions, WASHINGTON, April 8, ... the Bills to four consecutive Super,Bowls, will be on ... with,Members of Congress asking them to approve and fund ... also participate in a press event with Senators Christopher,Dodd ...
Cached Medicine News:Health News:Linkwell Corporation Year-End 2007 Earnings Release and Conference Call Notice 2Health News:Bayada Nurses Advocates for Increase in Medicaid Reimbursement Rate to Allow More Individuals to Receive Home Care and Hire More Skilled Staff 2Health News:IABC/Detroit Announces April Professional Development and Networking Events 2Health News:Double binding sites on tumor target may provide future combination therapy 2Health News:Pro Football Hall of Fame Member Jim Kelly Urges Congress to Approve the Newborn Screening Saves Lives Act 2Health News:Pro Football Hall of Fame Member Jim Kelly Urges Congress to Approve the Newborn Screening Saves Lives Act 3Health News:Pro Football Hall of Fame Member Jim Kelly Urges Congress to Approve the Newborn Screening Saves Lives Act 4
PEACOCK from NOMOS is a complete treatment,planning and delivery system exclusively designed,to support intensity modulated radiation therapy,(IMRT). PEACOCK is comprised of two breakthrough,...
... Novalis, BrainLAB's dedicated system ... and radiotherapy (SRS/SRT), represents ... precise treatments of brain ... & neck tumors, arteriovenous ...
... Oncor brings together Siemens existing patented ... MLC, and Virtual Wedge, with the ... workflow, patient position offset determination, and ... provide maximum efficiency of treatment delivery ...
Clinac Platinum Plus accelerators offer all the high performance features of the EX series and come with the latest high-precision dose sculpting technology for advanced tumor control....
Medicine Products: